{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:32:06Z","timestamp":1792459926731,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12072-022-10475-9","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T11:04:53Z","timestamp":1674731093000},"page":"291-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Sofosbuvir\/velpatasvir\/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan"],"prefix":"10.1007","volume":"17","author":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chu","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Da","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Tsai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Jen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Jhang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lueng","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Hsuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh-Chou","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yueh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jow-Jyh","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Wei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyh-Jou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai\u2010Yuan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"10475_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"Polaris Observatory HCV Collaborators","year":"2022","unstructured":"Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7:396\u2013415","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10475_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41\u201352","journal-title":"N Engl J Med"},{"key":"10475_CR3","first-page":"2051","volume":"9","author":"CH Liu","year":"2014","unstructured":"Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine. 2014;9:2051\u20132067","journal-title":"Int J Nanomedicine"},{"key":"10475_CR4","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594\u20131603","journal-title":"N Engl J Med"},{"key":"10475_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1\u201313","journal-title":"Ann Intern Med"},{"key":"10475_CR6","doi-asserted-by":"crossref","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","DOI":"10.1056\/NEJMoa1402454"},{"key":"10475_CR7","doi-asserted-by":"crossref","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, et al; ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599\u2013607.","DOI":"10.1056\/NEJMoa1512610"},{"key":"10475_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354\u2013369","journal-title":"N Engl J Med"},{"key":"10475_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","volume":"151","author":"GN Ioannou","year":"2016","unstructured":"Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, et al. Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology. 2016;151:457\u201371.e5","journal-title":"Gastroenterology"},{"key":"10475_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/jgh.13912","volume":"33","author":"CH Liu","year":"2018","unstructured":"Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, et al. Real-world effectiveness and safety of paritaprevir\/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. J Gastroenterol Hepatol. 2018;33:710\u2013717","journal-title":"J Gastroenterol Hepatol"},{"key":"10475_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209299","volume":"13","author":"CH Liu","year":"2018","unstructured":"Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, et al. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS ONE. 2018;13: e0209299","journal-title":"PLoS ONE"},{"key":"10475_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","volume":"72","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Carri\u00f3n JA, Curry M, Turnes J, Cornberg M, Negro F, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72:1112\u20131121","journal-title":"J Hepatol"},{"key":"10475_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/liv.14295","volume":"40","author":"CH Liu","year":"2020","unstructured":"Liu CH, Liu CJ, Hung CC, Hsieh SM, Su TH, Sun HY, et al. Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection: real-world effectiveness and safety in Taiwan. Liver Int. 2020;40:758\u2013768","journal-title":"Liver Int"},{"key":"10475_CR14","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1111\/liv.14537","volume":"40","author":"A Mangia","year":"2020","unstructured":"Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran SD, Carrat F, et al. Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts. Liver Int. 2020;40:1841\u20131852","journal-title":"Liver Int"},{"key":"10475_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12072-021-10158-x","volume":"15","author":"CH Liu","year":"2021","unstructured":"Liu CH, Chen PY, Chen JJ, Lo CC, Su WW, Tseng KC, et al. Sofosbuvir\/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. Hepatol Int. 2021;15:338\u2013349","journal-title":"Hepatol Int"},{"key":"10475_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14656566.2016.1182156","volume":"17","author":"L Ben\u00edtez-Guti\u00e9rrez","year":"2016","unstructured":"Ben\u00edtez-Guti\u00e9rrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17:1215\u20131223","journal-title":"Expert Opin Pharmacother"},{"key":"10475_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40265-018-0895-5","volume":"78","author":"YA Heo","year":"2018","unstructured":"Heo YA, Deeks ED. Sofosbuvir\/velpatasvir\/voxilaprevir: a review in chronic hepatitis C. Drugs. 2018;78:577\u2013587","journal-title":"Drugs"},{"key":"10475_CR18","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","unstructured":"AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67:1477\u20131492","journal-title":"Clin Infect Dis"},{"key":"10475_CR19","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170\u20131218","journal-title":"J Hepatol"},{"key":"10475_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","volume":"10","author":"M Omata","year":"2016","unstructured":"Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702\u2013726","journal-title":"Hepatol Int"},{"key":"10475_CR21","doi-asserted-by":"crossref","unstructured":"Bourli\u00e8re M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134\u201346.","DOI":"10.1056\/NEJMoa1613512"},{"key":"10475_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(18)30118-3","volume":"3","author":"M Bourli\u00e8re","year":"2018","unstructured":"Bourli\u00e8re M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, et al. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Lancet Gastroenterol Hepatol. 2018;3:559\u2013565","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10475_CR23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","volume":"71","author":"J Llaneras","year":"2019","unstructured":"Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, Garc\u00eda-Samaniego J, et al. Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol. 2019;71:666\u2013672","journal-title":"J Hepatol"},{"key":"10475_CR24","doi-asserted-by":"crossref","unstructured":"Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, et al; NAVIGATORE-Lombardia and Veneto Study Groups. Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019;71:1106\u201315.","DOI":"10.1016\/j.jhep.2019.07.020"},{"key":"10475_CR25","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","volume":"26","author":"PS Belperio","year":"2019","unstructured":"Belperio PS, Shahoumian TA, Loomis TP, Backus LI. Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients. J Viral Hepat. 2019;26:980\u2013990","journal-title":"J Viral Hepat"},{"key":"10475_CR26","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1093\/cid\/ciaa1510","volume":"72","author":"FQ Onofrio","year":"2021","unstructured":"Onofrio FQ, Cooper C, Borgia SM, Vachon ML, Ramji A, Lilly LB, et al. Salvage therapy with sofosbuvir\/velpatasvir\/voxilaprevir in DAA-experienced patients: results from a prospective Canadian registry. Clin Infect Dis. 2021;72:e799-805","journal-title":"Clin Infect Dis"},{"key":"10475_CR27","doi-asserted-by":"publisher","first-page":"e3288","DOI":"10.1093\/cid\/ciaa1318","volume":"73","author":"T Papaluca","year":"2021","unstructured":"Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, MacQuillan G, et al. Efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus (HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics. Clin Infect Dis. 2021;73:e3288\u2013e3295","journal-title":"Clin Infect Dis"},{"key":"10475_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/MEG.0000000000001786","volume":"33","author":"BL Da","year":"2021","unstructured":"Da BL, Lourdusamy V, Kushner T, Dieterich D, Saberi B. Efficacy of sofosbuvir\/velpatasvir\/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. Eur J Gastroenterol Hepatol. 2021;33:859\u2013861","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10475_CR29","doi-asserted-by":"crossref","unstructured":"Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, et al; REACH-C Study Group. Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort. J Viral Hepat. 2022;29:661\u20137.","DOI":"10.1111\/jvh.13705"},{"key":"10475_CR30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.jfma.2020.06.013","volume":"119","author":"CH Liu","year":"2020","unstructured":"Liu CH, Su TH, Liu CJ, Chen PJ, Chen DS, Kao JH. Sofosbuvir\/velpatasvir\/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: implications for viral elimination in Taiwan. J Formos Med Assoc. 2020;119:1871\u20131875","journal-title":"J Formos Med Assoc"},{"key":"10475_CR31","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1111\/jgh.15918","volume":"37","author":"YJ Wong","year":"2022","unstructured":"Wong YJ, Kumar R, Kumar R, Tan J, Liu CH, Hui VK, et al. Treatment outcomes of sofosbuvir\/velpatasvir\/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: real-world data from a multicenter Asian registry. J Gastroenterol Hepatol. 2022;37:1642\u20131644","journal-title":"J Gastroenterol Hepatol"},{"key":"10475_CR32","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1128\/JCM.03548-14","volume":"53","author":"CH Liu","year":"2015","unstructured":"Liu CH, Liang CC, Liu CJ, Lin CL, Su TH, Yang HC, et al. Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for hepatitis C virus genotyping. J Clin Microbiol. 2015;53:1754\u20131757","journal-title":"J Clin Microbiol"},{"key":"10475_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","volume":"137","author":"D Prati","year":"2002","unstructured":"Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1\u201310","journal-title":"Ann Intern Med"},{"key":"10475_CR34","doi-asserted-by":"publisher","unstructured":"Liu CH, Lin JW, Liu CJ, Su TH, Wu JH, Tseng TC, et al. Long-term evolution of estimated glomerular filtration rate in patients with antiviral treatment for hepatitis C virus infection. Clin Gastroenterol Hepatol 2022. https:\/\/doi.org\/10.1016\/j.cgh.2022.01.050. Epub ahead of print. PMID: 35131346.","DOI":"10.1016\/j.cgh.2022.01.050"},{"key":"10475_CR35","doi-asserted-by":"crossref","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 2006;43:1317\u201325.","DOI":"10.1002\/hep.21178"},{"key":"10475_CR36","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","volume":"69","author":"C Sarrazin","year":"2018","unstructured":"Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdley KV, Roberts SK, et al. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. J Hepatol. 2018;69:1221\u20131230","journal-title":"J Hepatol"},{"key":"10475_CR37","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.15011","volume":"48","author":"CH Liu","year":"2018","unstructured":"Liu CH, Yu ML, Peng CY, Hsieh TY, Huang YH, Su WW, et al. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Aliment Pharmacol Ther. 2018;48:1290\u20131300","journal-title":"Aliment Pharmacol Ther"},{"key":"10475_CR38","doi-asserted-by":"crossref","unstructured":"Liu CH, Liu CJ, Su TH, Fang YJ, Yang HC, Chen PJ, et al. Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection. Open Forum Infect Dis. 2017;4:ofx028.","DOI":"10.1093\/ofid\/ofx028"},{"key":"10475_CR39","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","volume":"11","author":"J Xie","year":"2022","unstructured":"Xie J, Xu B, Wei L, Huang C, Liu W. Effectiveness and Safety of Sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis. Infect Dis Ther. 2022;11:1661\u20131682","journal-title":"Infect Dis Ther"},{"key":"10475_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jhep.2019.05.021","volume":"71","author":"E Wilson","year":"2019","unstructured":"Wilson E, Covert E, Hoffmann J, Comstock E, Emmanuel B, Tang L, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir\/velpatasvir\/voxilaprevir in patients with or without HIV (RESOLVE STUDY). J Hepatol. 2019;71:498\u2013504","journal-title":"J Hepatol"},{"key":"10475_CR41","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.14309\/ajg.0000000000000248","volume":"114","author":"B Pearlman","year":"2019","unstructured":"Pearlman B, Perrys M, Hinds A. Sofosbuvir\/velpatasvir\/voxilaprevir for previous treatment failures with glecaprevir\/pibrentasvir in chronic hepatitis C infection. Am J Gastroenterol. 2019;114:1550\u20131552","journal-title":"Am J Gastroenterol"},{"key":"10475_CR42","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/jvh.13067","volume":"26","author":"P Ruane","year":"2019","unstructured":"Ruane P, Strasser SI, Gane EJ, Hyland RH, Shao J, Dvory-Sobol H, et al. Sofosbuvir\/velpatasvir\/voxilaprevir for patients with HCV who previously received a sofosbuvir\/velpatasvir-containing regimen: results from a retreatment study. J Viral Hepat. 2019;26:770\u2013773","journal-title":"J Viral Hepat"},{"key":"10475_CR43","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693\u2013705","journal-title":"Br J Pharmacol"},{"key":"10475_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/liv.14283","volume":"40","author":"K Ing Lorenzini","year":"2020","unstructured":"Ing Lorenzini K, Girardin F. Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients. Liver Int. 2020;40:32\u201344","journal-title":"Liver Int"},{"key":"10475_CR45","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jhep.2019.11.014","volume":"72","author":"CH Liu","year":"2020","unstructured":"Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, et al. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. J Hepatol. 2020;72:839\u2013846","journal-title":"J Hepatol"},{"key":"10475_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12072-018-9915-5","volume":"13","author":"T Kanda","year":"2019","unstructured":"Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, et al. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2019;13:103\u2013109","journal-title":"Hepatol Int"},{"key":"10475_CR47","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1111\/liv.15075","volume":"41","author":"S Patel","year":"2021","unstructured":"Patel S, Martin MT, Flamm SL. Sofosbuvir\/velpatasvir\/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. Liver Int. 2021;41:3024\u20133027","journal-title":"Liver Int"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10475-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10475-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10475-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T12:46:12Z","timestamp":1701780372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10475-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10475"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10475-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2215740\/v1","asserted-by":"object"}]},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"assertion":[{"value":"29 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chen-Hua Liu: advisory board for Abbvie, Gilead Sciences, Merck Sharp & Dohme; speaker\u2019s bureau for Abbott, Abbvie, Gilead Sciences, Merck Sharp & Dohme; research grant from Abbvie, Gilead Science, Merck Sharp & Dohme. Sheng-Shun Yang: advisory board for Abbvie, Roche, Ipsen; speaker\u2019s bureau for Abbvie, Bristol-Myers Squibb, Gilead Sciences, Ipsen, Merck Sharp & Dohme. Jia- Horng Kao: advisory board for Abbott, Abbvie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche; speaker\u2019s bureau for Abbott, Abbvie, Bayer, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Roche. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was not an animal research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal research"}},{"value":"The study was approved by the Research Ethics Committee of each participating center (ID: 202109016RIND) and was conducted in accordance with the principles of the Declaration of Helsinki in 1975.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each participant consented to this work and provided informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors consented the publish the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}